STOCK TITAN

Olink Holding Ab (Publ) - OLK STOCK NEWS

Welcome to our dedicated page for Olink Holding Ab (Publ) news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding Ab (Publ) stock.

Company Overview

Olink Holding AB (Publ) (symbol: OLK) is a specialized company dedicated to accelerating the field of proteomics. With a focus on advancing biomarker discovery and providing innovative solutions, Olink has established itself as a key contributor to modern clinical research and healthcare innovation. The company develops a platform of products and services designed to address critical needs in proteomics analysis, supporting both academic inquiry and pharmaceutical development.

Core Business Areas

Olink operates at the intersection of biotechnology and clinical research, providing a comprehensive portfolio that enables detailed protein analysis. The company specializes in:

  • Proteomics Platforms: Offering advanced tools that allow for the multiplexed analysis of protein biomarkers, thereby facilitating a deep understanding of human physiology.
  • Analytical Services: Delivering expert support and high-quality analytical services to biopharmaceutical companies and research institutions that leverage Olink's technology.
  • Research Collaboration: Partnering with leading academic and clinical organizations to drive innovative discoveries across multiple disease areas.

Market Position and Relevance

Positioned within the competitive life sciences and biotechnology industries, Olink plays a pivotal role in bridging advanced scientific research with practical healthcare applications. Its robust proteomics platform is integrated into various sectors of the healthcare ecosystem, including drug discovery, clinical diagnostics, and personalized medicine. By contributing actionable insights into cellular processes and disease biomarkers, Olink enhances the capability of researchers to make informed scientific decisions that underpin modern therapeutic strategies.

Technological Excellence

Olink’s solutions are built on cutting-edge proteomics technology that emphasizes accuracy, sensitivity, and high-throughput capability. The platform is engineered to handle the complexities of real-time human biology, offering scientists the tools necessary to detect subtle changes in protein expression. This precision technology not only supports targeted biomarker research but also contributes to a broader understanding of complex biological systems.

Global Footprint and Collaborations

Headquartered in Uppsala, Sweden, Olink has established a strong international presence with proven track records across Europe, North America, and Asia. The company collaborates with a diverse range of stakeholders including leading clinical laboratories, biopharmaceutical companies, and academic institutions. Such collaborations facilitate the integration of advanced proteomic data into research protocols and therapeutic development, underscoring Olink’s commitment to supporting global scientific innovation.

Operational Insights

The business model of Olink is built on delivering high-quality, reproducible proteomics solutions that cater to the evolving needs of the scientific community. The company emphasizes a balanced mix of product innovation and service excellence, ensuring its platform is both accessible and adaptable to a variety of research contexts. Its operations revolve around continuous refinement of assay technologies and platform integration, which in turn supports robust experimental design in clinical research settings.

Impact on Healthcare and Research

Olink’s work has significant implications for modern healthcare, particularly in the realm of early disease detection and personalized medicine. By enabling the detailed profiling of proteins, the company contributes to a deeper understanding of disease mechanisms and therapeutic response. The resulting insights drive more nuanced clinical strategies and foster innovations that improve patient outcomes without relying on speculative future outcomes.

Competitive Landscape

Within the dynamic field of biotechnology, Olink distinguishes itself through its commitment to quality data and scientific rigor. Unlike companies that emphasize volume over precision, Olink’s strategy centers on delivering precise, actionable proteomic data that equips researchers with a clearer picture of biological processes. This focus on excellence, alongside strategic collaborations with high-profile scientific institutions, reinforces its standing as a respected entity in the proteomics arena.

Conclusion

In summary, Olink Holding AB (Publ) offers a robust and scientifically validated suite of proteomics solutions that empower researchers to explore and understand the complexities of human biology. Its commitment to enhancing biomarker discovery, paired with a global, collaborative approach, cements its role as an essential player in the scientific community. The company’s integrated platform, built on technological innovation and expert application, highlights its significance in driving impactful advances in healthcare and biotechnology.

Rhea-AI Summary

Olink Holding AB has announced an Extra General Meeting (EGM) scheduled for August 6, 2024, at 4:00 p.m. CEST in Uppsala, Sweden. Shareholders must register by July 31, 2024, and be listed in Euroclear Sweden AB's share register by July 29, 2024, to participate. The meeting will cover the election of a new Chairman and Board members, with Anthony Smith proposed as Chairman. Electronic participation will be available, subject to approval. Proxy voting is allowed, with forms accessible online from July 16, 2024. The agenda includes voting on the number of Board members, their remuneration, and electing Board members. Olink has 124,739,269 shares, equating to the same number of votes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Thermo Fisher Scientific (NYSE: TMO) has successfully completed its acquisition of Olink Holding AB (Nasdaq: OLK) for $3.1 billion. This strategic acquisition enhances Thermo Fisher's capabilities in the high-growth proteomics market, integrating Olink’s advanced proteomics solutions with Thermo Fisher's mass spectrometry and life sciences offerings.

The transaction was executed via a tender offer where Thermo Fisher's subsidiary, Orion Acquisition AB, acquired approximately 98.2% of Olink’s outstanding shares at $26.00 per share or ADS. The initial offering period expired on July 9, 2024, and a subsequent offering period will run until July 16, 2024.

Post-acquisition, Olink will be delisted from Nasdaq and deregistered, affecting the liquidity of remaining ADSs. Thermo Fisher aims to expedite scientific breakthroughs and deliver significant shareholder value through this acquisition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-100%
Tags
-
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) announced that the UK Competition and Markets Authority (CMA) has unconditionally approved the tender offer by Orion Acquisition, a subsidiary of Thermo Fisher Scientific (NYSE: TMO), for all outstanding shares of Olink at $26.00 per share. The offer follows a Purchase Agreement from October 17, 2023. With CMA's approval, Olink and Thermo Fisher plan to complete the offer promptly after its expiration on July 9, 2024, at 5:00 p.m. ET. The offer is subject to conditions, including that the Buyer must hold more than 90% of the issued and outstanding common shares at the expiration time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
Rhea-AI Summary

On July 5, 2024, Olink Holding AB held an Extra General Meeting (EGM) in Uppsala, Sweden. During the meeting, several resolutions were adopted, including a decision to provide additional compensation to the board of directors. This compensation, proposed by the majority shareholder, amounts to USD 127,504 and will be distributed in tranches over multiple years. The details of these resolutions are available on the company's website.

For further information, investors can reach out to David Deuchler of the Gilmartin Group or Michael B. Gonzales, VP of Global Marketing, using the provided contact details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
Rhea-AI Summary

Olink Holding has launched its first-ever network of Olink Certified Service Providers, encompassing leading CROs and service labs worldwide. These certified providers have undergone rigorous training, testing, and re-certification to ensure top-notch performance using Olink's advanced proteomics technology.

Mike Irwin, Olink's Vice President, emphasized the goal of democratizing proteomics, making their platform accessible to researchers globally. The network includes prominent organizations such as AssayGate, Australian Genome Research Facility, and Vanderbilt University Medical Center, among others, facilitating convenient, high-quality access to Olink's cutting-edge solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (publ) has announced an Extra General Meeting scheduled for July 5, 2024, at Salagatan 16A, Uppsala. Registration starts at 3:30 p.m. CET. Shareholders must be registered by Euroclear Sweden AB by June 27, 2024, and notify their attendance by July 1, 2024. Electronic participation is possible if pre-approved, but such participants must vote through a proxy attending in person. Key agenda items include electing a meeting chairman, approving the agenda, and deciding on board member fees. The majority shareholder proposes additional fees for board members, totaling USD 127,504 until the 2028 AGM, with varied amounts payable upon a change of control. Olink has 124,739,269 shares and votes in total. Shareholders can request meeting-related information as specified under Swedish law.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) has launched the Olink Target 48 Immune Surveillance panel. This validated multiplexed protein assay panel provides an in-depth analysis of the immune system, monitoring inflammation and immune response using only 1μL of sample. When combined with the Olink Target 48 Cytokine panel, it can detect up to 89 immune-related proteins using just 2μL of sample. The panel uses Olink’s PEA™ technology and offers precise, quantitative data, aiding research in immunology, immuno-oncology, and infectious diseases. It aims to reduce import barriers and is compatible with the Olink Signature Q100 benchtop system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) announced a breakthrough study using its Olink Explore platform, showing proteins in blood may indicate cancer up to 7 years before diagnosis. Published in Nature Communications, the study analyzed blood from over 44,000 people, identifying 371 proteins associated with 19 cancers, including 107 detectable years before cancer onset. Conducted by Oxford Population Health and funded by Cancer Research UK, the findings highlight proteomics' potential for early cancer detection and better treatment. Further research is needed to confirm these proteins' roles in cancer. The study's details will be presented at the European Society of Human Genetics conference in Berlin, June 1-4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (publ) announced its first quarter 2024 financial results, showing revenue growth of 5% year over year to $28.8 million. Explore customer installations reached 121, and Signature Q100 placements reached 202. Net loss for the quarter was $(16.1) million, with adjusted EBITDA of $(15.5) million. Thermo Fisher Scientific acquisition expected to be completed by mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
Rhea-AI Summary
The Annual General Meeting of Olink Holding AB (publ) on April 19, 2024, adopted resolutions including approving balance sheets, remuneration to the Board of Directors, re-election of Board Members and auditor, incentive programs, and authorization for new share issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none

FAQ

What is the current stock price of Olink Holding Ab (Publ) (OLK)?

The current stock price of Olink Holding Ab (Publ) (OLK) is $26.08 as of February 7, 2025.

What is the market cap of Olink Holding Ab (Publ) (OLK)?

The market cap of Olink Holding Ab (Publ) (OLK) is approximately 3.2B.

What is the core business of Olink Holding AB?

Olink focuses on accelerating proteomics research by providing advanced platforms and services that enable detailed protein analysis and biomarker discovery. Its offerings support both academic and biopharmaceutical research initiatives.

How does Olink generate its revenue?

Olink generates revenue primarily through the sale of its proteomics platforms, analytical services, and research collaborations. The business model centers on delivering high-quality, reproducible data to support scientific studies.

Who are the primary users of Olink's technologies?

The company serves a diverse range of stakeholders including biopharmaceutical companies, clinical research centers, and academic institutions. These users leverage Olink’s advanced proteomics data to drive research and therapeutic development.

What differentiates Olink's proteomics platform from its competitors?

Olink stands out due to its emphasis on precision, sensitivity, and high-throughput capability in protein analysis. Its technology is designed to generate reproducible, actionable data that supports in-depth biological insights without compromising on quality.

How does Olink collaborate with the scientific community?

Olink collaborates with leading academic institutions and clinical research organizations to integrate advanced proteomics data into various studies. These partnerships help facilitate innovative research and contribute to a deeper understanding of disease mechanisms.

What global markets does Olink serve?

Olink maintains a strong international presence, operating in key markets across Europe, North America, and Asia. Its global outreach ensures that researchers worldwide can access its advanced proteomics solutions.

How does Olink impact modern healthcare?

By enabling detailed profiling of protein biomarkers, Olink enhances early disease detection and supports personalized medicine approaches. This capability assists researchers and clinicians in developing more informed and effective treatment strategies.

How does Olink maintain its competitive advantage?

Olink’s competitive advantage lies in its commitment to technological innovation and scientific excellence. The company continuously refines its assays and platforms, ensuring that it provides reliable and comprehensive data that support actionable research insights.
Olink Holding Ab (Publ)

Nasdaq:OLK

OLK Rankings

OLK Stock Data

3.24B
41.90M
66.41%
35.24%
2.03%
Diagnostics & Research
Healthcare
Link
Sweden
Uppsala